China Pharma Holdings (CPHI) Gains from Investment Securities (2010 - 2026)
China Pharma Holdings (CPHI) reported Gains from Investment Securities of -$1446.0 for Q1 2026, up 98.93% quarter-over-quarter from -$135320.0 in Q4 2025.
China Pharma Holdings (CPHI) Gains from Investment Securities (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Gains from Investment Securities for 10 years, with the latest figure at -$1446.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to -$1446.0; the trailing twelve-month figure through Mar 2026 stood at -$341077.0 (changed N/A YoY), and the FY2025 full-year result was $10000.0, down 99.93% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$1446.0, up from -$135320.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $13.6 million in Q4 2024, with the low at -$204518.0 in Q3 2023.
- Historically, Gains from Investment Securities has averaged $2.6 million across 4 years, with a median of -$1446.0 in 2026.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 6565117.39% — and 2025, when it plunged 101.0%.
- China Pharma Holdings' Gains from Investment Securities stood at $207.0 in 2023, then surged by 6565117.39% to $13.6 million in 2024, then sank by 101.0% to -$135320.0 in 2025, then surged by 98.93% to -$1446.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$1446.0 (Q1 2026), -$135320.0 (Q4 2025), and $13.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,446.00 |
| Mar 31, 2026 | -1,446.00 |
| Dec 31, 2025 | -135,320.00 |
| Dec 31, 2025 | -135,320.00 |
| Dec 31, 2024 | 13.59 Mn |
| Dec 31, 2024 | 13.59 Mn |
| Dec 31, 2023 | 207.00 |
| Dec 31, 2023 | 207.00 |
| Sep 30, 2023 | -204,518.00 |
| Sep 30, 2023 | -204,518.00 |
| Dec 31, 2021 | 519.00 |
| Dec 31, 2021 | 519.00 |
| Sep 30, 2021 | 10.00 |
| Sep 30, 2021 | 10.00 |
| Dec 31, 2019 | -1,486.00 |
| Dec 31, 2019 | -1,486.00 |
| Sep 30, 2019 | -2,499.00 |
| Sep 30, 2019 | -2,499.00 |
| Jun 30, 2019 | -2,426.00 |
| Jun 30, 2019 | -2,426.00 |